AgomAb Therapeutics (NASDAQ:AGMB) Stock Rating Lowered by Wall Street Zen

AgomAb Therapeutics (NASDAQ:AGMB) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Sunday, Wall Street Zen reports.

A number of other research firms have also recently weighed in on AGMB. HC Wainwright restated a “buy” rating on shares of AgomAb Therapeutics in a research note on Wednesday, September 16th. B. Riley Financial began coverage on AgomAb Therapeutics in a research note on Thursday, July 23rd. They issued a “buy” rating and a $34.00 price target for the company. Cantor Fitzgerald initiated coverage on AgomAb Therapeutics in a report on Wednesday, August 19th. They set an “overweight” rating on the stock. Finally, Piper Sandler assumed coverage on AgomAb Therapeutics in a research report on Tuesday, August 25th. They issued an “overweight” rating and a $60.00 price objective on the stock. Seven investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, AgomAb Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $37.50.

AgomAb Therapeutics Trading Down 2.9%

Shares of NASDAQ:AGMB opened at $10.21 on Friday. The stock has a 50 day moving average of $13.17 and a 200 day moving average of $12.19. AgomAb Therapeutics has a 12-month low of $8.75 and a 12-month high of $17.82.

AgomAb Therapeutics (NASDAQ:AGMB) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.46) earnings per share for the quarter. As a group, research analysts expect that AgomAb Therapeutics will post -1.76 earnings per share for the current year.

AgomAb Therapeutics Company Profile

AgomAb Therapeutics N.V. (NASDAQ: AGMB) is a clinical-stage biopharmaceutical company developing medicines for diseases involving tissue damage, fibrosis and impaired regeneration. The company’s approach includes modulating biological pathways that influence tissue repair and remodeling, with the goal of addressing conditions with significant unmet medical needs.

AgomAb’s lead clinical program is AGMB-129, an oral, gut-restricted inhibitor of activin receptor-like kinase 5 (ALK5), a receptor involved in transforming growth factor beta signaling.